Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arrivent Biopharma Inc (AVBP)

Arrivent Biopharma Inc (AVBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,005,192
  • Shares Outstanding, K 41,281
  • Annual Sales, $ 0 K
  • Annual Income, $ -80,490 K
  • EBIT $ -162 M
  • EBITDA $ -162 M
  • 60-Month Beta 0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.04

Options Overview Details

View History
  • Implied Volatility 111.51% (+20.16%)
  • Historical Volatility 62.75%
  • IV Percentile 50%
  • IV Rank 48.38%
  • IV High 192.43% on 09/16/25
  • IV Low 35.69% on 09/05/25
  • Expected Move (DTE 14) 0.72 (2.87%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 168
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 6,820
  • Open Int (30-Day) 6,062
  • Expected Range 24.42 to 25.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.84
  • Number of Estimates 4
  • High Estimate -0.81
  • Low Estimate -0.91
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.77 +41.47%
on 11/07/25
25.28 -0.53%
on 12/05/25
+6.81 (+37.15%)
since 11/05/25
3-Month
17.00 +47.88%
on 11/03/25
25.28 -0.53%
on 12/05/25
+4.95 (+24.52%)
since 09/05/25
52-Week
15.47 +62.51%
on 04/07/25
29.86 -15.81%
on 12/09/24
-3.41 (-11.94%)
since 12/05/24

Most Recent Stories

More News
ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17...

AVBP : 24.89 (+2.22%)
ArriVent Appoints Brent S. Rice as Chief Commercial Officer

NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative...

AVBP : 24.89 (+2.22%)
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Confirmed overall response rate (cORR) 68.2% and duration...

AVBP : 24.89 (+2.22%)
ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025 Dosed the first patient...

AVBP : 24.89 (+2.22%)
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent...

AVBP : 24.89 (+2.22%)
New Strong Sell Stocks for July 21st

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Cadiz CDZI acquires and develops water-related land and agricultural assets. The Zacks Consensus Estimate for its current year...

ACCO : 3.58 (+0.56%)
AVBP : 24.89 (+2.22%)
CDZI : 5.85 (-0.34%)
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

AVBP : 24.89 (+2.22%)
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

AVBP : 24.89 (+2.22%)
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

AVBP : 24.89 (+2.22%)
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

AVBP : 24.89 (+2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent BioPharma Inc. is based in NEWTOWN SQUARE, Pa.

See More

Key Turning Points

3rd Resistance Point 27.38
2nd Resistance Point 26.19
1st Resistance Point 25.27
Last Price 24.89
1st Support Level 23.16
2nd Support Level 21.97
3rd Support Level 21.05

See More

52-Week High 29.86
Last Price 24.89
Fibonacci 61.8% 24.36
Fibonacci 50% 22.67
Fibonacci 38.2% 20.97
52-Week Low 15.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar